Table 3 Multivariable Cox analysis for advanced prostate patients with prior cancer (vs. no prior cancer)

From: Effect of prior cancer on survival outcomes for patients with advanced prostate cancer

Characteristic Overall survival Prostate cancer-specific survival
HR (95 % CI) P HR (95 % CI) P
All patients 1.13 (1.02–1.26) 0.017 0.93 (0.81–1.06) 0.248
Part I: Prior cancer timing
(vs. no prior cancer)
    
≤ 1 year 1.35 (1.11–1.66) 0.003 0.80 (0.60–1.08) 0.152
1–2 year 1.27 (1.02–1.57) 0.033 0.97 (0.72–1.29) 0.818
2–3 year 1.18 (0.93–1.49) 0.176 0.78 (0.56–1.09) 0.150
3–5 year 1.14 (0.94–1.37) 0.180 0.97 (0.77–1.23) 0.792
5–10 year 1.05 (0.89–1.24) 0.535 0.93 (0.76–1.15) 0.512
>10 year 1.11 (0.92–1.33) 0.270 1.09 (0.88–1.35) 0.432
Part II: Prior cancer stage
(vs. no prior cancer)
    
In situ 1.13 (0.87–1.47) 0.365 0.90 (0.64–1.27) 0.539
Localized 1.05 (0.91–1.21) 0.537 0.87 (0.73–1.05) 0.139
Regional 1.27 (0.97–1.68) 0.083 0.91 (0.70–1.19) 0.488
Distant 1.31 (1.08–1.58) 0.007 0.77 (0.51–1.16) 0.206
Part III: Prior cancer type
(vs. no prior cancer)
    
Urinary bladder 1.39 (1.16–1.66) < 0.001 0.98 (0.77–1.26) 0.880
Colon and cecum 1.23 (1.02–1.48) 0.034 0.67 (0.67–1.11) 0.243
Melanoma of the skin 1.02 (0.70–1.19) 0.502 0.93 (0.68–1.26) 0.618
Non-hodgkin lymphoma 1.16 (0.89–1.52) 0.277 1.22 (0.89–1.65) 0.213
Rectum 1.10 (0.81–1.48) 0.546 0.78 (0.52–1.19) 0.250
Lung and bronchus 1.54 (1.15–2.08) 0.004 0.90 (0.58–1.42) 0.658
Kidney and renal pelvis 0.79 (0.57–1.09) 0.154 0.70 (0.47–1.06) 0.096
Chronic lymphocytic leukemia 1.47 (1.01–2.15) 0.046 1.10 (0.66–1.85) 0.707
larynx 1.06 (0.64–1.76) 0.819 0.94 (0.50–1.78) 0.850
Others 1.05 (0.89–1.24) 0.576 0.92 (0.77–1.14) 0.447
  1. HR hazard ratio, CI confidence interval
  2. The multivariate analysis was adjusted for age, race, marital status, histologic grade, and treatment modalities (surgery, chemotherapy, and radiation)